Saturday, December 2, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Disclosures for additional planners can be found here.
Director
Institute of Experimental Cancer Research
University Hospital Ulm
Ulm, Germany
CLL Clinical Nurse Specialist
The Russell Centre for Clinical Haematology
Nottingham University Hospitals
Nottingham, United Kingdom
Medical Director
Hematology Department
Niguarda Cancer Center
Milan, Italy
Professor
Harvard Medical School
Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Chair
CLL Advocates Network
Leukemia Patient Advocates Foundation
Bern, Switzerland
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This educational activity is intended for an international audience of non-US hematologists/oncologists, pathologists, cardiologists and other healthcare providers involved in the care of patients with B-cell malignancies.
The goal of this activity is for learners to be better able to use BTK inhibitors for the individual patient with B-cell malignancies.
Upon completion of this activity, participants will:
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Disclosures for additional planners can be found here.
Director
Institute of Experimental Cancer Research
University Hospital Ulm
Ulm, Germany
CLL Clinical Nurse Specialist
The Russell Centre for Clinical Haematology
Nottingham University Hospitals
Nottingham, United Kingdom
Medical Director
Hematology Department
Niguarda Cancer Center
Milan, Italy
Professor
Harvard Medical School
Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Chair
CLL Advocates Network
Leukemia Patient Advocates Foundation
Bern, Switzerland
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Developed through a partnership between Medscape and CLL Advocates Network.
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.50 continuing professional development credits (CPD).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must
complete the activity online during the credit eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CPD Released: 11/7/2022
Valid for credit through: 11/7/2023, 11:59 PM EST
processing....
The goal of this activity is for learners to be better able to use BTK inhibitors for the individual patient with B-cell malignancies.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
